Home Cart Sign in  
Chemical Structure| 1469439-69-7 Chemical Structure| 1469439-69-7

Structure of Cabamiquine
CAS No.: 1469439-69-7

Chemical Structure| 1469439-69-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DDD107498 is a multiple-stage antimalarial agent targeting on eEF2.

Synonyms: DDD107498; DDD-498; MMV121

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cabamiquine

CAS No. :1469439-69-7
Formula : C27H31FN4O2
M.W : 462.56
SMILES Code : O=C(C1=CC(C2=CC=C(CN3CCOCC3)C=C2)=NC4=CC=C(F)C=C14)NCCN5CCCC5
Synonyms :
DDD107498; DDD-498; MMV121
MDL No. :MFCD32204416
InChI Key :BENUHBSJOJMZEE-UHFFFAOYSA-N
Pubchem ID :71748268

Safety of Cabamiquine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2/C3A cells 3.58 nM(EC50) 24 h To evaluate the inhibitory effect of Cabamiquine on hepatic stage Plasmodium infection. Results showed that Cabamiquine did not affect hepatocyte viability at tested concentrations and effectively inhibited Plasmodium growth. ACS Infect Dis. 2025 Jan 10;11(1):69-79
Plasmodium falciparum clinical isolates 7.5 nM (15× EC50) 6 days Evaluate the susceptibility of clinical isolates to Cabamiquine Nat Commun. 2023 Aug 25;14(1):5205

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NMRI mice P. berghei ANKA infection model Oral 0.3 mg/kg, 0.6 mg/kg, 1.5 mg/kg Single dose, monitored up to 37 days To evaluate the preventive effect of Cabamiquine on hepatic stage Plasmodium infection in vivo. Results showed that Cabamiquine at 1.5 mg/kg completely prevented the appearance of blood stage parasites. ACS Infect Dis. 2025 Jan 10;11(1):69-79
NOD/SCID/IL2rγnull (NSG) mice Humanized mouse model Oral 12 mg/kg Single dose Evaluate the antimalarial efficacy and resistance mutations of Cabamiquine in a mouse model Nat Commun. 2023 Aug 25;14(1):5205

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.16mL

0.43mL

0.22mL

10.81mL

2.16mL

1.08mL

21.62mL

4.32mL

2.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories